147 related articles for article (PubMed ID: 24672331)
1. Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Li H; Li X; Ma H; Wang Y; Fu N; Jin D; Cong H
ScientificWorldJournal; 2014; 2014():565367. PubMed ID: 24672331
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.
Wu H; Li D; Fang M; Han H; Wang H
J Clin Pharmacol; 2015 Feb; 55(2):123-31. PubMed ID: 25310898
[TBL] [Abstract][Full Text] [Related]
3. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
4. [Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
Su JZ; Xue Y; Cai WQ; Huang QY; Chai DJ; Chen GL; Wang FB; Chen XP; Zhang DS
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Sep; 39(9):807-11. PubMed ID: 22321227
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.
Ozhan H; Erden I; Ordu S; Aydin M; Caglar O; Basar C; Yalcin S; Alemdar R
Angiology; 2010 Oct; 61(7):711-4. PubMed ID: 20395226
[TBL] [Abstract][Full Text] [Related]
7. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
8. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention.
Fu N; Liang M; Yang S
Angiology; 2018 Sep; 69(8):692-699. PubMed ID: 29343076
[TBL] [Abstract][Full Text] [Related]
9. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Athyros VG; Karagiannis A; Ganotakis ES; Paletas K; Nicolaou V; Bacharoudis G; Tziomalos K; Alexandrides T; Liberopoulos EN; Mikhailidis DP;
Curr Med Res Opin; 2011 Aug; 27(8):1659-68. PubMed ID: 21714711
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
Li W; Fu X; Wang Y; Li X; Yang Z; Wang X; Geng W; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
Cardiology; 2012; 122(3):195-202. PubMed ID: 22854323
[TBL] [Abstract][Full Text] [Related]
11. Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease.
Katsiki N; Elisaf M
Curr Med Res Opin; 2011 Aug; 27(8):1669-72. PubMed ID: 21718096
[No Abstract] [Full Text] [Related]
12. Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. Randomized, controlled, open-label, prospective pilot study.
Oh J; Kang SM; Hong N; Youn JC; Park S; Lee SH; Choi D
Circ J; 2014; 78(10):2447-54. PubMed ID: 25168278
[TBL] [Abstract][Full Text] [Related]
13. Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.
Wang Y; Shi Y; Xu X; Ge W; Yang S; Lu C
Medicine (Baltimore); 2019 Jun; 98(25):e16049. PubMed ID: 31232940
[TBL] [Abstract][Full Text] [Related]
14. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Liu Y; Liu YH; Tan N; Chen JY; Zhou YL; Li LW; Duan CY; Chen PY; Luo JF; Li HL; Wei-Guo
PLoS One; 2014; 9(10):e111124. PubMed ID: 25357250
[TBL] [Abstract][Full Text] [Related]
16. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes.
Sun Y; Qi G; Gao Y; Zhang H; Pang X; Zhao W; Zhang Z
Can J Cardiol; 2010 Nov; 26(9):481-5. PubMed ID: 21076721
[TBL] [Abstract][Full Text] [Related]
17. Hypouricemic effect of statins: another pleiotropic benefit?
López-Cuenca A; Roldán V; Marín F
J Thorac Cardiovasc Surg; 2010 May; 139(5):1358-9. PubMed ID: 20412974
[No Abstract] [Full Text] [Related]
18. Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography.
Acikel S; Muderrisoglu H; Yildirir A; Aydinalp A; Sade E; Bayraktar N; Bal U; Ozin B
Blood Coagul Fibrinolysis; 2010 Dec; 21(8):750-7. PubMed ID: 20962623
[TBL] [Abstract][Full Text] [Related]
19. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury.
Quintavalle C; Fiore D; De Micco F; Visconti G; Focaccio A; Golia B; Ricciardelli B; Donnarumma E; Bianco A; Zabatta MA; Troncone G; Colombo A; Briguori C; Condorelli G
Circulation; 2012 Dec; 126(25):3008-16. PubMed ID: 23147173
[TBL] [Abstract][Full Text] [Related]
20. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study.
Athyros VG; Mikhailidis DP; Liberopoulos EN; Kakafika AI; Karagiannis A; Papageorgiou AA; Tziomalos K; Ganotakis ES; Elisaf M
Nephrol Dial Transplant; 2007 Jan; 22(1):118-27. PubMed ID: 16998214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
